Effects of synthetic versus natural colloid resuscitation on inducing dilutional coagulopathy and increasing hemorrhage in rabbits

Journal of Trauma - Injury, Infection and Critical Care

Volumn 64, Issue 5, 2008, Pages 1218-1228

  Kheirabadi, Bijan S ^a   Crissey, Jacqueline M ^a   Deguzman, Rodolfo ^a   Perez, Michael R ^a   Cox, Ashley B ^a   Dubick, Michael A ^a   Holcomb, John B ^a  

^a US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

Author keywords

5 albumin; Dextran 70; Dilutional coagulopathy; Hemostasis; Hextend; Rabbit; Splenic hemorrhage

Indexed keywords

ALBUMIN; DEXTRAN 70; FIBRINOGEN; HETASTARCH; HUMAN ALBUMIN; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL GAS; ARTICLE; BATTLE INJURY; BLEEDING; BLOOD CELL COUNT; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; BLOOD PRESSURE; BLOOD TRANSFUSION; COLLOID; CONCENTRATION RESPONSE; DEATH; HEMATOCRIT; HEMODILUTION; HEMOSTASIS; HYPOTHERMIA; LAPAROTOMY; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PH; PRIORITY JOURNAL; PROTHROMBIN TIME; RABBIT; RESUSCITATION; SPLEEN INJURY; SURVIVAL TIME; THROMBIN TIME; THROMBOCYTE; THROMBOELASTOGRAPHY;

ANIMALS; BLOOD GAS ANALYSIS; COLLOIDS; DISSEMINATED INTRAVASCULAR COAGULATION; HEMATOCRIT; HEMODILUTION; HEMORRHAGE; HETASTARCH; ISOTONIC SOLUTIONS; MALE; PLASMA SUBSTITUTES; RABBITS; RESUSCITATION; SPLEEN;

EID: 43449087038     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e31816c5c6c     Document Type: Article

References (66)

1. Velanovich V. Crystalloid versus colloid fluid resuscitation; a meta-analysis of mortality. Surgery. 1989;105:65-71.
2. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systemic review of randomized trials. BMJ. 1998;316:961-964.
3. Choi PT, Yip G, Quinonez LG, Cook DJ. Crystalloids vs. colloids in fluid resuscitation: a systemic review. Crit Care Med. 1999;27:200-210.
4. Alderson P, Schierhout G, Roberts I, Bunn F. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2000;2:CD000567.
5. Fakhry SM, Alexander J, Smith D, Meyer AA, Peterson HD. Regional and institutional variation in burn care. J Burn Care Rehabil. 1995;16:86-90.
6. American College of Surgeon, Committee on Trauma. Advanced Trauma Life Support Manual. Chicago: American College of Surgeons; 1997:21-60.
7. Zajtchuk R, Jenkins DP, Bellamy FR, et al, eds. Combat Casualty Care Guidelines for Operation Desert Storm. Washington, DC: Office of the Army Surgeon General Publication; 1991.
8. Butler FK, Hagmann J. Butler EG. Tactical combat casualty care in special operations. Mil Med. 1996;161(suppl):3-16.
9. Tremblay LN, Rizoli SB, Brenneman FD. Advances in fluid resuscitation of hemorrhagic shock. Can J Surg. 2001;44:172-179.
10. Ferreira EL, Terzi RG, Silva WA, de Moraes AC. Early colloid replacement therapy in a near-fatal model of hemorrhagic shock. Anesth Analg. 2005;101:1785-1791.
11. Stump DC, Strauss RG, Henriksen RA, Peterson RE, Saunders R. Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion. 1985;25:349-354.
12. Jamnicki M, Bombeli T, Seifert B, et al. Low- and medium-molecular-weight hydroxyethyl starches: comparison of their effect on blood coagulation. Anesthesiology. 2000;93:1231-1237.
13. Arellano R, Gan BS, Salpeter MJ, et al. A triple-blinded randomized trial comparing the hemostatic effects of large-dose 10% hydroxyethyl starch 264/0.45 versus 5% albumin during major reconstructive surgery. Anesth Analg. 2005;100:1846-1853.
14. Jonville-Bera AP, Autret-Leca E, Gruel Y. Acquired type I von Willebrand's disease associated with highly substituted hydroxyethyl starch. N Engl J Med. 2001;345:622-623.
15. de Jonge E, Levi M, Buller HR, Berends F, Kesecioglu J. Decreased circulating levels of von willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. Intensive Care Med. 2001; 27:1825-1829.
16. Strogemuller B, Stark J, Willschke H, Felfernig M, Hoerauf K, Kozek-Langenecker SA. The effect of hydroxyethyl starch 200 kD on platelet function. Anesth Analg. 2000;91:823-827.
17. Franz A, Braunilich P, Gamsjager T, Felfernig M, Gustorff B, Kozek-Langenecker SA. The effects of hydroxyethyl starches of varying molecular weights on platelet function. Anesth Analg. 2001; 92:1402-1407.
18. Nielsen VG. Effects of hextend hemodilution on plasma coagulation kinetics in the rabbit: role of factor XIII-mediated fibrin polymer crosslinking. J Surg Res. 2006;132:17-22.
19. Nielsen VG. Colloids decrease clot propagation and strength: role of factor XIII-fibrin polymer and thrombin-fibrinogen interactions. Acta Anaesthesiol Scand. 2005;49:1163-1171.
20. Lucas CE, Denis R, Ledgerwood AM, Grabow D. The effects of Hespan on serum and lymphatic albumin, globulin, and coagulant protein. Ann Surg. 1988;207:416-420.
21. Lucas CE, Ledgerwood AM, Mammen EF. Altered coagulation protein content after albumin resuscitation. Ann Surg. 1982;196:198-202.
22. Alexander B, Odake K, Lawlor D, Swanger M. Coagulation, hemostasis, and plasma expanders: a quarter century enigma. Fed Proc. 1975;34:1429-1440.
23. Bergqvist D. Dextran and haemostasis. a review. Acta Chir Scand. 1982;148:633-640.
24. Nilsson IM, Eiken O. Further studies on the effect of dextran of various molecular weight on the coagulation mechanism. Thromb Diath Haemorrh. 1964;11:38-50.
25. Holcomb JB, McMullin NR, Pearse L, et al. Causes of death in U.S. special operation forces in the global war on terrorism: 2001-2004. Ann Surg. 2007;245:986-991.
26. Institute of Laboratory Animal Resources, National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
27. Pusateri AE, Ryan KL, Delgado AV, et al. Effects of increasing doses of activated recombinant factor VII on haemostatic parameters in swine. Thromb Haemost. 2005;93:275-283.
28. Boura C, Caron A, Longrois D, Mertes PM, Labrude P, Menu P. Volume expansion with modified hemoglobin solution, colloids, or crystalloid after hemorrhagic shock in rabbits: effects in skeletal muscle oxygen pressure and use versus arterial blood velocity and resistance. Shock. 2003;19:176-182.
29. Kheirabadi BS, Crissey JM, Deguzman R, Holcomb JB. In vivo bleeding time and in vitro thrombelastography measurements are better indicators of dilutional hypothermic coagulopathy than prothrombin time. J Trauma. 2007;62:1352-1359; discussion 1359-1361.
30. McCammon AT, Wright JP, Figueroa M, Nielsen VG. Hemodilution with albumin, but not Hextend, results in hypercoagulability as assessed by Thrombelastography in rabbits: role of heparin-dependent serpins and factor VIII complex. Anesth Analg. 2002;95:844-850.
31. Niemi TT, Kuitunen AH. Hydroxyethyl starch impairs in vitro coagulation. Acta Anaesth Scand. 1998;42:1104-1109.
32. Mortier E, Ongenae M, De Baerdemaeker L, et al. In vitro evaluation of the effect of profound haemodilution with hydroxyethyl starch 6%, modified fluid gelatin 4% and dextran 40 10% on coagulation profile measured by thromboelastography. Anaesthesia. 1997;52:1061-1064.
33. Petroianu GA, Liu J, Maleck, Mattinger C, Bergler WF. The effect of in vitro hemodilution with gelatin, dextran, hydroxyethyl starch, or Ringer's solution on thrombelastograph. Anesth Analg. 2000; 90:795-800.
34. De Jonge E, Levi M. Plasma substitutes on blood coagulation: a comparative review. Crit Care Med. 2001;29:1261-1267.
35. Lockwood DN, Bullen C, Machin SJ. A severe coagulopathy following volume replacement with hydroxyethyl starch in a Jehovah's Witness. Anaesthesia. 1988;43:391-393.
36. Boldt J, Knothe C, Zickemann B, Andres P, Dapper F, Hempelmann G. Influence of different intravascular volume therapies on platelet function in patients undergoing cardiopulmonary bypass. Anesth Analg. 1993;76:1185-1190.
37. Wilkes MM, Navickis RJ, Sibbald WJ. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding. Ann Thorac Surg. 2001;72:527-533; discussion 534.
38. Gan TJ, Glass PS, Sigl J, et al. Hextend, a physiologically balanced plasma expander for large volume use in major surgery: a randomized phase III clinical trial. Hextend Study Group. Anesth Analg. 1999;88:992-998.
39. Kirklin JK, Lell WA, Kouchoukos NT. Hydroxyethyl starch versus albumin for colloid infusion following cardiopulmonary bypass in patients undergoing myocardial revascularization. Ann Thorac Surg. 1984;37:40-46.
40. Moggio RA, Rha CC, Somberg ED, Praeger PI, Pooley RW, Reed GE. Hemodynamic comparison of albumin and hydroxyethyl starch in postoperative cardiac surgery patients. Crit Care Med. 1983; 11:943-945.
41. Knutson JE, Deering JA, Hall FW, et al. Does intraoperative hetastarch administration increase blood loss and transfusion requirements after cardiac surgery? Anesth Analg. 2000;90: 801-807.
42. Cope JT, Banks D, Mauney MC, et al. Intraoperative hetastarch infusion impairs hemostasis after cardiac operations. Ann Thorac Surg. 1997;63:78-82; discussion 82-83.
43. Nielsen VG, Tan S, Brix AE, Baird MS, Parks DA. Hextend (hetastarch solution) decreases multiple organ injury and xanthine oxidase release after hepatoenteric ischemia-reperfusion in rabbits. Crit Care Med. 1997;25:1565-1574.
44. Dailey SH, Kobler JB, Hillman RE, et al. An in vitro study comparing the effects of Hextend, Hespan, normal saline, and lactated ringer's solution on thrombelastography and the activated partial thromboplastin time. J Cardiothorac Vasc Anesth. 2005; 19:358-361.
45. Jamnicki M, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn DR. Compromised blood coagulation: an in vitro comparison of hydroxyethyl starch 130/0.4 and hydroxyethyl starch 200/0.5 using thrombelastography. Anesth Analg. 1998;87:989-993.
46. Entholzner EK, Mielke LL, Calatizis AN, Fevh J, Hipp R, Hargasser SR. Coagulation effects of a recently developed hydroxyethyl starch (HES 130/0.4) compared to hydroxyethyl starches with higher molecular weight. Acta Anaesthesiol Scand. 2000;44:1116-1121.
47. Roche AM, James MF, Bennett-Guerrero E, Mythen MG. A head-to-head comparison of the in vitro coagulation effects of saline-based and balanced electrolyte crystalloid and colloid intravenous fluids. Anesth Analg. 2006;102:1274-1279.
48. Boldt J, Brosch C, Suttner S, Haisch G, Kumle B, Schellhaass A. Effects of a new modified, balanced hydroxyethyl starch preparation (Hextend) on measures of coagulation. Br J Anaesth. 2002;89:722-728.
49. Kasper SM, Meinert P, Kampe S, et al. Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses. Anesthesiology. 2003;99:42-47.
50. Wiedermann CJ. Hydroxyethyl starch - can the safety problems be ignored? Wien Klin Wochenschr. 2004;116:583-594.
51. Paul M, Dueck M, Joachim Herrmann H, Holzki J. A randomized, controlled study of fluid management in infants and toddlers during surgery: hydroxyethyl starch 6% (HES 70/0.5) vs. lactated Ringer's solution. Paediatr Anaesth. 2003;13:603-608.
52. Jungheinrich C, Neff TA. Pharmacokinetics of hydroxyethyl starch. Clin Pharmacokinet. 2005;44:681-699.
53. Nielsen VG. Hemodilution modulates the time of onset and rate of fibrinolysis in human and rabbit plasma. J Heart Lung Transplant. 2006;25:1344-1352.
54. Thaler U, Deusch E, Kozek-Langenecker SA. In vitro effects of gelatin solutions on platelet function: a comparison with hydroxyethyl starch solutions. Anaesthesia. 2005;60:554-559.
55. Deusch E, Gamsjager T, Kress H, Kozek-Langenecker S. Binding of hydroxyethyl starch molecules to the platelet surface. Anesth Analg. 2003;97:680-683.
56. Alexander B. Effects of plasma expanders on coagulation and hemostasis: dextran, hydroxyethyl starch and other macromolecules revisited. In: Jamieson GA, Greenwalt TJ, eds. Blood Substitutes and Plasma Expanders. Prog Clin Biol Res. 1978;19:293-298.
57. Kovalik SG, Ledgewood AM, Lucas CE, Higgins RF. The cardiac effect of altered calcium homeostasis after albumin resuscitation. J Trauma. 1981;21:275-279.
58. Denis R, Smith RW, Grabow D, Ledgerwood AM, Lucas CE. Relocation of nonalbumin proteins after albumin resuscitation. J Surg Res. 1987;43:413-419.
59. Groeneveld AB. Albumin and artificial colloids in fluid management: where does the clinical evidence of their utility stand? Crit Care. 2000;4(Suppl 2):S16-S20.
60. Lang K, Boldt J, Suttner S, Haisch G. Colloids versus crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery. Anesth Analg. 2001;93:405-409.
61. Human albumin administration in critically ill patients: systematic review of randomized controlled trials. Cochrane injuries group albumin reviewers. BMJ. 1998;317:235-240.
62. Wilkes MM, Navickis RJ. Patient survival after human albumin administration: a meta-analysis of randomized, controlled trials. Ann Inter Med. 2001;135:149-164.
63. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. SAFE Study investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004; 350:2247-2256.
64. SAFE Study Investigators. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med. 2007; 357:874-884.
65. Champion HR. Combat fluid resuscitation: introduction and overview of conferences. J Trauma. 2003;54:S7-S12.
66. Dubick MA, Bruttig SP, Wade CE. Issues of concern regarding the use of hypertonic/hyperoncotic fluid resuscitation of hemorrhagic hypotension. Shock. 2006;25:321-328.